KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Cash from Operations (2016 - 2025)

Jazz Pharmaceuticals (JAZZ) has 16 years of Cash from Operations data on record, last reported at 362518000.0 in Q4 2025.

  • For Q4 2025, Cash from Operations fell 9.05% year-over-year to 362518000.0; the TTM value through Dec 2025 reached 1355773000.0, down 2.88%, while the annual FY2025 figure was 1355773000.0, 2.88% down from the prior year.
  • Cash from Operations reached 362518000.0 in Q4 2025 per JAZZ's latest filing, down from 474616000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 474616000.0 in Q3 2025 and bottomed at 41695000.0 in Q2 2021.
  • Average Cash from Operations over 5 years is 294708600.0, with a median of 305115500.0 recorded in 2022.
  • Peak YoY movement for Cash from Operations: tumbled 77.16% in 2021, then surged 626.79% in 2022.
  • A 5-year view of Cash from Operations shows it stood at 177755000.0 in 2021, then skyrocketed by 92.38% to 341971000.0 in 2022, then crashed by 51.07% to 167339000.0 in 2023, then soared by 138.19% to 398580000.0 in 2024, then decreased by 9.05% to 362518000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Operations were 362518000.0 in Q4 2025, 474616000.0 in Q3 2025, and 88855000.0 in Q2 2025.